Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Must have histologically confirmed squamous cell carcinoma or adenosquamous cell carcinoma of esophagus~* Male or Female at least 18 years of age~* Must have esophageal cancer that cannot be operated on, or treated with definitive chemoradiation with curative intent, that is advanced, reoccurring or has spread out~* Must have full activity or, if limited, must be able to walk and carry out light activities such as light house work or office work~* Must agree to provide tumor tissue sample, either from a previous surgery or biopsy within 6 months or fresh, prior to the start of treatment in this study~Exclusion Criteria~* Presence of tumor cells in the brain or spinal cord which are symptomatic or require treatment~* Active known or suspected autoimmune disease~* Any serious or uncontrolled medical disorder or active infection~* Known history of positive test for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS)~* Any positive test result for hepatitis B or C indicating acute or chronic infection and/or detectable virus~Other protocol defined inclusion/exclusion criteria apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nivolumab + Ipilimumab (Type: EXPERIMENTAL): None
- Nivolumab + Cisplatin + Fluorouacil (Type: EXPERIMENTAL): None
- Cisplatin + Fluorouracil (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).